Where to Start: A Beginner's Guide to Choosing Your First Research Compound

The criteria experienced researchers use to evaluate a starting compound come down to four questions. First, evidence depth: how much published research exists for this compound? More published research means more mechanistic understanding, more replication from independent groups, and more data to design your protocol from. Second, mechanism clarity: is the mechanism well characterized, or is it hypothesized but not yet confirmed? Compounds with clearly established mechanisms allow for better protocol design and more interpretable results.

Third, safety data: how well is the tolerance profile characterized? More published safety data means fewer unknowns in the risk assessment. Fourth, relevance: does the compound address the specific biological question you are investigating? The best starting compound for recovery research is not the same as the best starting compound for cognitive research.

Applying these four criteria consistently will guide you toward well evidenced, clearly mechanistic compounds that are appropriate for the research area you are entering.

BPC-157 is arguably the most studied peptide in the recovery and repair research space — with hundreds of published papers spanning gastrointestinal protection, musculoskeletal repair, angiogenesis, and neurological applications. Its mechanisms are among the best characterized of any research peptide: angiogenesis via VEGF and NO pathways, fibroblast activation, and gut lining protection. Multiple independent research groups across multiple countries have studied it. The evidence base is deep.

TB-500 — the thymosin beta 4 fragment — is close behind BPC-157 in the recovery research space. Its actin regulation mechanism and cell migration facilitation have been studied in cardiac, musculoskeletal, and wound healing contexts. The combination of BPC-157 and TB-500 is the most studied and most mechanistically justified combination in the recovery peptide literature.

For researchers new to the recovery research space, starting with BPC-157 and reviewing its literature thoroughly before expanding to other compounds is the approach most consistent with the published evidence base.

Selank and Semax are the most evidence supported starting points for cognitive research — distinguished from all other research peptides by their clinical registration status in Russia. Both have completed controlled clinical trials with human subjects. Both have decades of published mechanistic and clinical literature. Both have characterized human safety profiles from actual clinical use.

Selank is the appropriate starting point if the research focus is anxiety adjacent — GABAergic modulation, stress resilience, mood related cognitive effects. Semax is the appropriate starting point if the focus is performance adjacent — BDNF driven cognitive enhancement, neuroprotection, dopaminergic modulation. The two compounds complement each other and are sometimes studied together.

For researchers entering the cognitive space, the ability to reference actual clinical trial data is a significant advantage. The Russian Institute of Molecular Genetics literature is the starting point — these papers provide the mechanistic foundation and the clinical framing that the international literature builds on.

NAD+ has one of the largest published research bases of any compound in this catalog — the NAD+ aging biology literature spans major research institutions including Harvard, MIT, and the Salk Institute, with decades of rigorous published research. The sirtuin mechanism, the PARP mechanism, and the electron transport chain cofactor role are among the best characterized molecular mechanisms in all of aging biology. For researchers entering metabolic or longevity research, NAD+ provides the deepest and most rigorously published foundation.

MOTS-c is newer — the discovery paper was published in 2015 — but the mitochondrial DNA-encoded peptide story is one of the most compelling in recent biology research. The AMPK mechanism is well characterized and the exercise metabolism connection is well documented. For researchers specifically interested in mitochondrial signaling and metabolic adaptation, MOTS-c represents a genuinely novel and increasingly well studied research area.

These two compounds address different levels of metabolic biology: NAD+ at the cofactor supply level, MOTS-c at the intercellular metabolic signaling level. Starting with NAD+ for its deeper evidence base and broader mechanistic context, then adding MOTS-c, is the approach consistent with evidence depth prioritization.

GHK-Cu has a published research history exceeding 50 years — beginning with Loren Pickart's 1973 isolation of the tripeptide from human plasma and continuing through decades of collagen synthesis, wound healing, hair follicle, and gene expression research. This longevity of published research gives GHK-Cu the deepest single compound evidence base for tissue and skin research of any compound in this catalog.

Both topical and systemic research pathways are well documented, providing flexibility in research approach depending on the specific tissue target. The gene expression research — showing broad modulation of over 4,000 genes toward a regenerative pattern — makes GHK-Cu particularly interesting for researchers studying aging biology at the transcriptional level.

For researchers focused on skin, wound healing, hair follicle biology, or gene expression modulation, GHK-Cu's 50-year evidence base and comprehensive mechanism characterization make it the most natural starting point.

The most important variable in any research peptide protocol is not which compound you choose — it is where you get it. A perfectly designed protocol with a contaminated or mislabeled compound generates useless data at best and harmful results at worst. The compound must be what it claims to be, at the purity it claims to be, with the documentation to verify both.

Research grade means independently verified purity (≥98% by HPLC), confirmed molecular identity (mass spectrometry matching the expected molecular weight), and a batch specific COA from a reputable third party analytical laboratory. A COA without a batch number, without a third party stamp, or that cannot be independently verified is not meaningful documentation.

This single quality standard — batch specific COA with independent third party verification — is the minimum requirement for any research compound you work with. It is not an optional extra for the careful researcher. It is the baseline.

Having chosen a starting compound based on the four criteria (evidence depth, mechanism clarity, safety data, relevance), the next step is reading the primary literature — not summaries, not forum discussions, but actual published papers. PubMed searches for the compound name plus its mechanism will return the foundational papers. The reference lists at the bottom of each compound guide in this research hub provide curated starting points.

After reviewing the literature, read the compound's specific guide in this research hub — it covers the mechanism, the evidence tiers, the protocol information from published research, and the quality specifications.

Then review the COA documentation for the specific batch you will be working with. Verify the purity and identity data. Understand the reconstitution and storage requirements. Design your protocol based on the published literature. And keep records of everything.